Amikacin inhalation - Nektar Therapeutics/Bayer HealthCare

Drug Profile

Amikacin inhalation - Nektar Therapeutics/Bayer HealthCare

Alternative Names: Aerosolised amikacin; Amikacin inhale; BAY-416551; Inhaled amikacin; NKTR-061

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nektar Therapeutics
  • Developer Bayer HealthCare; Nektar Therapeutics
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gram-negative infections; Nosocomial pneumonia

Most Recent Events

  • 07 Apr 2017 Bayer completes the phase III INHALE 2 trial in Gram-negative infections and Nosocomial pneumonia in Belgium, China, France, Germany, Greece, Hungary, Israel, Italy, Japan, the Netherlands, Poland, Portugal, Russia, Spain, Ukraine, Czech Republic, Latvia (NCT00805168)
  • 06 Apr 2017 Bayer completes the phase III INHALE 1 trial in Gram-negative infections and Nosocomial pneumonia in USA, Argentina, Australia, Brazil, Canada, Colombia, Czech Republic, South Korea, Mexico, Philippines, Taiwan, Thailand, Turkey (NCT01799993)
  • 10 Dec 2015 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top